Amphastar Urges 1st Circ. To Nix Rivals' Antitrust Immunity

Law360, New York (December 20, 2016, 8:04 PM EST) -- Amphastar Pharmaceuticals Inc. urged the First Circuit on Monday to revive its suit accusing Momenta Pharmaceuticals Inc. and Sandoz Inc. of trying to block a competing generic version of a blood clot medication, accusing the drugmakers of trying to rewrite a district court decision to hold on to their antitrust immunity.

The specialty drugmaker told the First Circuit that a Massachusetts district court was wrong to conclude that the Noerr-Pennington doctrine protected Momenta from claims that it plotted with Sandoz to keep Amphastar from selling generic...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.